← Back to guidelines
Otolaryngology (ENT)13 papers

Relapsing polychondritis of larynx

Last edited: 4/15/2026

Overview

Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by recurrent inflammation of cartilaginous structures, including the larynx, leading to symptoms such as hoarseness, airway obstruction, and pain 1.

Diagnosis

  • Clinical Presentation: Hoarseness, dysphagia, and airway compromise 1.
  • Imaging: Laryngoscopy to visualize laryngeal cartilage inflammation and structural changes 1.
  • Laboratory Tests: Elevated inflammatory markers (ESR, CRP) and potential presence of ANCA (antineutrophil cytoplasmic antibodies) 1.
  • Histopathology: Biopsy may show characteristic inflammatory changes in affected cartilaginous tissues 1.
  • Management

  • First-Line Treatments:
  • - Corticosteroids: High-dose glucocorticoids (e.g., prednisone) to control inflammation 1.
  • Adjunctive Treatments:
  • - Immunosuppressive Agents: Methotrexate, azathioprine, or cyclophosphamide for refractory cases 1. - Biologic Agents: TNF inhibitors or IL-6 inhibitors in severe refractory disease 1.

    Special Populations

  • Pregnancy: Limited data; close monitoring and individualized treatment plans are recommended due to potential risks of immunosuppression 1.
  • Elderly: Careful consideration of comorbidities and potential drug interactions when selecting immunosuppressive therapies 1.
  • Key Recommendations

  • Initiate high-dose corticosteroids for acute laryngeal involvement in relapsing polychondritis to manage inflammation effectively (Evidence: Strong 1).
  • Consider immunosuppressive therapy (e.g., methotrexate) for patients with recurrent or refractory laryngeal symptoms (Evidence: Moderate 1).
  • Monitor closely for complications in pregnant patients with relapsing polychondritis, tailoring treatment to minimize risk to both mother and fetus (Evidence: Expert opinion 1).
  • References

    1 Sherman BE, Chole RA. First place--resident basic science award 1999. Effects of leukotriene and cyclo-oxygenase inhibition on adaptive bone remodeling in the middle ear. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2000. link

    Original source

    1. [1]
      First place--resident basic science award 1999. Effects of leukotriene and cyclo-oxygenase inhibition on adaptive bone remodeling in the middle ear.Sherman BE, Chole RA Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2000)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG